Skip to main content
Skip to footer
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
News Releases
Photo Corner
Video Corner
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
News Releases
Photo Corner
Video Corner
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
Publication Category:
Abstract
Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)
October 21, 2021
Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas MühlerNeurologyPublished: April 14, 2020
Home – 2
About
Pipeline
News
Publications
Investors
Career
Contact
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Vidofludimus Calcium
IMU-856
IMU-381
IR Home
News Releases
Events and Presentations
Stock Informations
Financials and SEC Filings
Corporate Governance
IR Contact
Search
Search
